You are here: Industry Insights > Velabs

News List

Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics b3cnewswire
January 16, 2020
Velabs Therapeutics GmbH (Velabs), a biotech company focused on the rapid screening of functional therapeutic antibodies announced that it has entered into an exclusive licence agreement with alytas therapeutics GmbH (alytas), for the development and ...
Velabs Therapeutics Enters into a Screening Cooperation with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening After b3cnewswire
August 30, 2019
Velabs Therapeutics, specializing in the fast generation of functional therapeutic antibodies, today announced that its cooperation with Chiome Bioscience, Inc., Tokyo, will be deepened...
Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme b3cnewswire
June 28, 2019
Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme.
Velabs Therapeutics to Cooperate with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening b3cnewswire
April 25, 2019
Velabs Therapeutics to Cooperate with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening.
Velabs collaborates with Chiome for GPCR-Specific functional antibody screening biospectrumasia
April 25, 2019
The collaboration will capitalize on Velabs’ microfluidics-based technology in the field of functional antibody screening